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Background: Growth factors are generally accepted to be essential mediators of tissue repair via well-establishedmecha-
nisms of action that include stimulatory effects on angiogenesis and cellullar proliferation, ingrowth, differentiation, andmatrix
biosynthesis.Theaimof this studywas toevaluate ina large-scale, prospective,blinded,and randomizedcontrolledclinical trial
the safety andeffectivenessof purified recombinant humanplatelet-derivedgrowth factor (rhPDGF-BB)mixedwith a synthetic
beta-tricalcium phosphate (b-TCP) matrix for the treatment of advanced periodontal osseous defects at 6 months of healing.
Methods: Eleven clinical centers enrolled 180 subjects, each requiring surgical treatment of a 4 mm or greater intrabony
periodontal defect and meeting all inclusion and exclusion criteria. Subjects were randomized into one of three treatment
groups: 1)b-TCP+ 0.3mg/ml rhPDGF-BB inbuffer; 2)b-TCP+ 1.0mg/ml rhPDGF-BB inbuffer; and3)b-TCP+ buffer (active
control). Safety data were assessed by the frequency and severity of adverse events. Effectiveness measurements included
clinical attachment levels (CAL) and gingival recession (GR) measured clinically and linear bone growth (LBG) and percent
bone fill (% BF) as assessed radiographically by an independent centralized radiology review center. The area under the curve
(AUC), an assessment of the rate of healing, was also calculated for CAL measurements. The surgeons, clinical and radio-
graphic evaluators, patients, and study sponsor were all masked with respect to treatment groups.
Results:CALgain was significantly greater at 3months for group 1 (rhPDGF0.3mg/ml) compared to group 3 (b-TCP +
buffer) (3.8 versus 3.3 mm; P = 0.032), although by 6 months, this finding was not statistically significant (P = 0.11). This
early acceleration of CAL gain led to group 1 exhibiting a significantly greater rate of CAL gain between baseline and 6
months thangroup 3 as assessed by theAUC (68.4- versus 60.1-mmweeks; P = 0.033). rhPDGF (0.3mg/ml)-treated sites
alsohadsignificantlygreater linearbonegain (2.6versus0.9mm,respectively;P<0.001)andpercentdefectfill (57%versus
18%, respectively; P <0.001) than the sites receiving the bone substitute with buffer at 6 months. There was less GR at 3
months in group 1 compared to group 3 (P = 0.04); at 6 months, GR for group 1 remained unchanged, whereas there
wasaslight gain in gingivalheight for group3 resulting in comparableGR.Therewereno seriousadverseeventsattributable
to any of the treatments.
Conclusions: To our knowledge, this study is the largest prospective, randomized, triple-blinded, and controlled pivotal
clinical trial reported to date assessing a putative periodontal regenerative and wound healing therapy. The study demon-
strated that the use of rhPDGF-BB was safe and effective in the treatment of periodontal osseous defects. Treatment with
rhPDGF-BB stimulated a significant increase in the rate of CAL gain, reduced gingival recession at 3months post-surgery,
and improved bone fill as compared to a b-TCP bone substitute at 6 months. J Periodontol 2005;76:2205-2215.
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P
eriodontal researchers and clinicians, in an ef-
fort to develop effective regenerative therapies,
have sought to understand key events involved
in the regeneration of the periodontium. An increased
knowledge of specific cellular response and function
within the periodontium has led to the development of
numerous treatment modalities exhibiting different
degrees of success. Treatments including ‘‘grafting’’
with bone or bone substitutes;1-17 stimulation of cells
with growth factors, hormones, or extracelluar matrix
proteins;6,7,18-25 cell occlusive barrier membranes for
selective cell growth in periodontal defects;26-32 and
modification of the tooth root surface33-38 have all
been explored for their ability to predictably regenerate
the periodontium. Although some treatments have
yielded promising results, there remains a need for
a treatment that leads to faster and more predictable
regeneration of the periodontium. Building on these
results, as well as knowledge gained from within the
field of tissue engineering, periodontal treatment
modalities now strive to provide one or more of the
following to enhance periodontal regeneration: appro-
priate matrices, biologic mediators, and/or precursor
cells. By providing these building blocks, the process
of regeneration may be enhanced, resulting in an ear-
lier and greater regenerative response.
The therapeutic system used in this study com-
bines purified recombinant (synthetic) human
platelet-derived growth factor (rhPDGF-BB) with a
biocompatible osteoconductive, synthetic scaffold
(beta-tricalcium phosphate [b-TCP]) for the treat-
ment of osseous defects resulting from periodontal
disease.
b-TCP is a purified, multicrystalline, and porous
form of calciumphosphatewith aCa/PO4 ratio similar
to natural bonemineral. Extensive animal and human
clinical studies over the past 25 years have demon-
strated the biocompatibility of b-TCP, including in-
corporation into host bone in various skeletal sites,
remodeling, and eventual replacement by the host
bone.39-42 b-TCP is marketed as a bone void filler
for orthopedic and dental applications worldwide.
PDGF is a well-characterized tissue growth factor
currently marketed in a gel formulation for the treat-
ment of chronic cutaneous ulcers in the lower extrem-
ities of diabetics. In periodontics, numerous studies
have demonstrated its mitogenic and chemotactic ef-
fects onperiodontal ligament (PDL) andalveolar bone
cells, as well as its ability to promote the regeneration
of bone, ligament, and cementum in animals and hu-
mans.6,7,22,24,43-55 An initial human clinical trial
demonstrated that the application of 0.15 mg/ml
rhPDGF-BB and 0.15 mg/ml recombinant human
insulin-like growth factor I (rhIGF-I) resulted in a
significant improvement of bone fill in periodontal de-
fects compared to conventional surgery plus a vehicle
control.22 Additionally, results of a pilot human trial
indicated that the application of 0.5 to 1.0 mg/ml
rhPDGF-BB in allograft resulted in the regeneration
of bone, ligament, and cementum as demonstrated
by blinded histologic evaluation.6,7
The aim of this randomized controlled trial (RCT)
was to evaluate the safety and efficacy of rhPDGF-




Male and female subjects, 25 to 75 years of age, each
with one interproximal periodontal defect requiring
surgical treatment, were included in the study. Other
inclusion criteria included the following: 1) a probing
depth measuring 7 mm or greater at baseline; 2) fol-
lowing debridement, a 4 mm or greater vertical bone
defect depth (BD)with at least one intact bonywall; 3)
sufficient keratinized tissue to allow complete tissue
coverage of the defect; 4) a radiographic base of
the defect at least 3 mm coronal to the apex of the
tooth; and 5) no evidence of localized aggressive
periodontitis. Smokers were allowed to use up to one
pack of cigarettes per day.
Patients were not admitted to the study if any of the
following criteria were present: 1) failure to maintain
adequate oral hygiene during the lead-in phase; 2)
pregnant women or women intending to become
pregnant during this study period; 3) history within
the last 6months of oral cancer or human immunode-
ficiency virus (HIV); 4) history within the last year of
previous periodontal surgery on the study tooth; 5)
the study tooth exhibiting mobility of greater than
grade 2; 6) the study tooth exhibiting a Class 3 furca-
tion defect; 7) clinical or radiographic signs of untreated
acute infection at the surgical site, apical pathology,
root fracture, severe root irregularities, cemental pearls;
cemento-enamel projections not easily removed by
odontoplasty, untreated carious lesions at the ce-
mento-enamel junction (CEJ) or on the root surface,
subgingival restorations and/or restorations with
open margins at or below the CEJ; 8) history within
the last 6 months of weekly or more frequent use of
smokeless chewing tobacco, pipe or cigar smoking,
or smokingmore than20cigarettes per day; 9) allergy
to yeast-derived products; or 10) subjects using an in-
vestigational therapy or approved therapy for investi-
gational use within 30 days of surgery.
Sample Size Calculation
The estimated sample size for this trial was calculated
using CAL and relied on the normal deviate distribu-
tions for a one-sided t test comparing two groups of
independent and randomly allocated subjects. Each
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participating individual contributed one osseous de-
fect to the trial.
The number of subjects needed per treatment
group was calculated using the following assump-
tions: N ‡2 (SD)2 (1.645 + 0.84)2 D2, where normal
deviate at a = 0.05 (one-sided) and at b = 0.20
(80% power); SD of CAL change = 2.0 mm; and de-
tectable difference (D) in CAL = 1.0 mm.
Whencomparing to the control (b-TCP +buffer), 50
subjects per group were required. Conservatively al-
lowing for a 15% attrition, each group was randomly
allocated 60 subjects to allow the statistical power
to be met.
Study Design and Procedures
This triple-blind, prospective, and parallel-arm RCT
was conducted at eleven clinical centers (of MN and
MLN, WVG, MKM, RTK, JTM, JEH, BSM, KSM, PKM,
DWP, and TJH) in subjects requiring surgical treat-
ment of a periodontal osseous defect. A meeting of
investigators was conducted prior to the study initia-
tion to train the investigators on the study protocol
including the standardization of patient selection,
measurement and surgical techniques, and postoper-
ative management. Eligible subjects were random-
ized in equal proportions to three treatment groups
of;60 subjects each (180 total patients) using a vari-
able block design: group 1: b-TCP, with buffer con-
taining 0.3 mg/ml rhPDGF-BB; group 2: b-TCP,
with buffer containing 1.0 mg/ml rhPDGF-BB; and
group 3: b-TCP, with buffer alone (active control).
Informed consent was obtained at the initial visit.
Subjects were assessed at the screening and baseline
visits to determine eligibility. Prior to initiating the
baselinemeasurements, intra- and interexaminer cal-
ibrations were performed on patients at each center to
ensure reproducibility and consistency by each inves-
tigator (intraexaminer) aswell as across all study cen-
ters (interexaminer). Each subject received standard
care, including full-mouth scaling, root planing, and
oral hygiene instruction within 2 months of the base-
line clinical measurements to minimize bacterial in-
sult and reduce variability between lesions at baseline.
Surgical treatment consisted of the administration
of local anesthesia followed by reflection of full thick-
ness buccal and lingual flaps to allow adequate visu-
alization of the treatment site. The osseous defect was
thoroughly debrided, and the root surfaces were planed
using hand, ultrasonic, and rotary instrumentation as
necessary to remove root surface accretions and
enamel projections. Direct measurements of the in-
trabony defect were then obtained, including vertical
BD, bone defect width (W) from the root surface to
the farthest bone wall, and the number of bone walls
present (i.e.,1 to 3). If the bone defect was ‡4 mm
vertically, final subject eligibility was confirmed, and
the tooth root surfaces were decontaminated with
a tetracycline paste prepared by mixing the contents
of one 250-mg capsule with sterile saline. A blinded
study kit was selected for each patient according to
a randomization schedule. The b-TCP wasmixed with
the buffer with or without rhPDGF-BB and allowed to
sit for ;10 minutes to permit binding of the rhPDGF-
BB protein to the b-TCP before being placed into the
osseous defect. The gingival flaps were then secured
with non-resorbable sutures to achieve complete soft
tissue coverage of the surgical site. The duration of the
study was 6 months following surgery. Postoperative
visits at days 3 to 5, 6 to 9, 12 to 15, and 19 to 24 and
weeks 6, 12, 18, and 24 were scheduled to monitor
safety and obtain clinical and radiographic data for
subsequent analysis. Following completion of the 6-
month assessments, surgical reentry was performed
on a small number of patients to visualize the area
of the original defect.
Endpoints
Effectiveness measurements included the soft-tissue
measurements change in gingival clinical attachment
level (CAL) and degree of post-surgical recession and
the hard tissue measurements radiographic linear
bone growth (LBG) and radiographic percent bone fill
(% BF) between baseline and 6 months post-surgery
comparing the rhPDGF-BB treated groups (groups 1
or 2) to the active control (group 3).
Radiographs were obtained within 2 months prior
to the baseline surgery using bite planes and paralle-
ling techniques andholders.†††Thequality of the films
was assessed by the investigator prior to the release of
the patient to ensure diagnostic quality. Radiographs
from all clinical centers were sent to a separate, inde-
pendent, centralized, and blinded radiographic center
(of MSR). The films were digitized, and linear radio-
graphic measurements were analyzed for bone
changes. The following measurements, illustrated in
Figure 1, were taken on the baseline and 6-month dig-
itized periapical radiographic images: CEJ to base of
bonedefect,CEJtocrestof bone,andCEJto root apex.
The following formula was used to determine LBG:
LBG = CEJ to base of defect at baseline - CEJ to base
of defect at 6 months.
Percent bone fill was calculated by dividing LBG by
the depth of the original bone defect. An initial pilot
study was performed on 25 radiographs to confirm
the feasibility of using these radiographic measure-
ments. A separate intraexaminer calibration was also
performed to confirm the reproducibility of the radio-
graphic measurements. This assessment included
a review of a representative sampling of radiographs
measured at two different time points (;1 month
††† Dentsply Rinn, Elgin, IL.
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apart) and demonstrated a 3% variability between
measurements.
For any paired baseline and 6-month radiographs
demonstrating ‡15% difference in the measurement
fromCEJ to root apex,measurements were corrected
for elongation or foreshortening.
Safety was monitored throughout the trial by as-
sessing the frequency and severity of adverse events
(clinical and radiographic). The relationship of each
adverse event to the treatment rendered (test or con-
trol) was assessed in a blinded fashion by the investi-
gator. All adverse events were reported regardless of
causality, including events that were normal sequelae
related to the surgical procedure.
The study was initiated following Food and Drug
Administration (FDA) and institutional review board
(IRB) approvals and was monitored for compliance
to good clinical practices (GCPs) by an independent
contract research organization (CRO).‡‡‡ Test mate-
rials§§§ were supplied to independent contract manu-
facturing facilitiesiii¶¶¶ where they were labeled using
masked rub-off labels according to a randomization
code generated by the CRO.
Statistical Methods
The sample size for this trial was calculated using the
outcome variable CAL, and relied on the normal devi-
ate distributions for a one-sided t test comparing two
groups of independent and randomly allocated sub-
jects. Each patient contributed one osseous defect
to the trial. The primary endpoint was change in
CAL between baseline and 6 months for group 1 ver-
sus group3.As prespecified in the statistical plan, sig-
nificance between groups 2 and 3was assessed only if
statistical significance was observed in the primary
comparison. Categorical measurements were dis-
played as counts and percents, and continuous vari-
ables were displayed as means, medians, standard
errors, and ranges. Statistical
comparisons between the
test product treatment groups
(groups 1 and 2) and the
control group (group 3) were
made using chi-square and
Fisher’s exact tests for cate-
gorical variables and t tests
or analysis of variance
(ANOVA) methods for contin-
uous variables. Comparisons
between treatment groups for
ordinal variables were made
usingCochran-Mantel-Haenszel
methods. An area under the
curve (AUC) analysis was per-
formed to assess the cumula-
tive change in CAL between
baseline and 6 months. P £0.05 (one-sided) was
considered to be statistically significant for AUC,
CAL, LBG, and % BF. A standard stratification of the
cumulative % BF was performed examining the distri-
bution of outcomes.
Safety and effectiveness data were 100% verified
against source documents, and the statistical analy-
ses were performed by the CRO. Safety data were as-
sessed by the frequency and severity of adverse
events as evaluated clinically and radiographically.
RESULTS
Demographics and Patient Follow-Up
There were no statistically significant differences in
clinical baseline characteristics observed among the
treatment groups (including CAL, PD, GR, and defect
location and classification) (Table 1). The patient
population was balanced for age, ethnicity, and gen-
der, and no significant differences were observed
among the three treatment groups for reported med-
ical and dental histories (Table 2). Follow-up was
completed on 178 of the 180 patients enrolled in
the trial (two were lost to follow-up). One patient
was disqualified from the efficacy analysis due to an
acute endodontic infection at baseline. Consequently,
the statistical analysis is based on clinical data from
177 patients (98.3%) and radiographs from 173 pa-
tients (96.1%). Four subjects were omitted from the
radiographic analysis because the films were not of
diagnostic quality.
Analyses to assess the reliability of CAL measure-
ments were performed by measuring the intraex-
aminer reproducibility and interexaminer consistency.
These analyses provided the measure of reliability
Figure 1.
Representative radiographic case from group 1 (0.3 mg/ml rhPDGF-BB) demonstrating the appearance
of bone fill in the original osseous defect. A) Baseline; B) 6 months post-surgery. Note the significant
increase in radiographic fill of the defect. Radiographic assessment found 3.11 mm LBG and 47% BF.
Arrows with numbers denote the following: 1) CEJ; 2) base of bone defect at baseline; 3) root apex; 4)
bone crest; and 5) new base of defect at 6 months.
‡‡‡ Target Health, New York, NY.
§§§ GEM 21S, BioMimetic Therapeutics, Franklin, TN.
iii Omnicare, King of Prussia, PA.
¶¶¶ Proclinical, Phoenixville, PA.
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(‘‘kappa’’) as follows: kappa = 0.9596 demonstrated
intraexaminer reproducibility; kappa = 0.8901 dem-
onstrated interexaminer consistency.
Effectiveness
The results from the statistical analyses revealed clin-
ical and radiographic benefits for the two treatment
groups incorporating 0.3 or 1.0 mg/ml rhPDGF-BB
(groups1and2, respectively), compared to the active
control, b-TCP, group (group 3). A representative
case treated with rhPDGF is shown in Figure 2.
At 3 months post-surgery, the mean CAL gain was
significantly greater in group 1 versus group 3 (3.8 –
0.2 versus 3.3 – 0.2 mm; P = 0.032), thereby indicat-
ing a significant early benefit of rhPDGF-BB for the
gain in CAL. At 6 months post-surgery, this trend
continued to favor group 1 over group 3 (mean gain
of 3.8 – 0.2 versus 3.5 – 0.2 mm, respectively), al-
though this difference was not statistically significant
(P = 0.107). Overall, this early acceleration of CAL
gain led to group 1 exhibiting a significantly greater
rate of CAL gain between baseline and 6 months than
group3asassessedby theAUC(68.4- versus60.1-mm
weeks; P =0.033) (Fig. 3). Additionally, therewas less
GR at 3 months in group 1 compared to group 3 (P =
0.04); at6months,GR forgroup1 remainedunchanged,
whereas there was a slight gain in gingival height for
group 3 resulting in comparable GR (P >0.05).
Table 1.
No Significant Difference in Baseline Clinical Characteristics Between Groups
Baseline Characteristics Group 1 (N = 60) Group 2 (N = 61) Group 3 (N = 59) P Value
CAL (mm)
Mean – SE 9.1 – 0.2 8.8 – 0.2 8.8 – 0.2 0.500*
Range 7 to 14 7 to 13 6 to 13
PD (mm)
Mean – SE 8.6 – 0.2 8.2 – 0.2 8.3 – 0.2 0.167*
Range 7 to 14 7 to 13 7 to 14
GR (mm)
Mean – SE 0.5 – 0.2 0.6 – 0.2 0.5 – 0.1 0.891*
Range -2 to 4 -2 to 5 -2 to 4
Defect location
Maxillary 21 (35%) 24 (39.3%) 18 (30.5%) 0.598*
Mandibular 39 (65%) 37 (60.7%) 41 (69.5%) 0.612†
MB 25 (41.7%) 27 (44.3%) 27 (45.8%)
B 0 (0.0%) 0 (0.0%) 0 (0.0%)
DB 21 (35.0%) 17 (27.9%) 15 (25.4%)
ML 8 (13.3%) 14 (23.0%) 10 (16.9%)
L 0 (0.0%) 0 (0.0%) 0 (0.0%)
DL 6 (10.0%) 3 (4.9%) 7 (11.9%)
Defect classification (coronal portion) 0.301†
1-wall 20 (33.3%) 17 (27.9%) 19 (32.2%)
2-wall 26 (43.3%) 32 (52.5%) 26 (44.1%)
3-wall 5 (8.3%) 8 (13.1%) 11 (18.6%)
Circumferential 9 (15.0%) 4 (6.6%) 3 (5.1%)
Defect tooth 0.713†
Multirooted 35 (58.3%) 33 (54.1%) 30 (50.8%)
Single-rooted 25 (41.7%) 28 (45.9%) 29 (49.2%)
Vertical bone defect depth (mm; mean – SE) 6.0 – 0.2 5.7 – 0.2 5.7 – 0.2 0.357*
Width of osseous defect (mean – SE) 3.7 – 0.2 3.5 – 0.1 3.7 – 0.1 0.606*
* P value (one-way ANOVA).
† P value (chi-square test).
MB = mesio-buccal; B = buccal; DB = disto-buccal; ML = mesio-lingual; L = lingual; DL = disto-lingual.
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In addition to the observed clinical benefits on the
soft tissue parameters of CAL and GR, radiographic
analyses of LBG and % BF revealed a significant im-
provement in bone gain for groups 1 or 2 versus group
3. A representative radiographic case for group 1 is
shown in Figure 1. LBG was significantly improved in
group 1 (2.6 – 0.2 mm) compared to group 3 (0.9 –
0.1 mm; P <0.001) and in group 2 (1.5 – 0.2 mm)
compared to group 3 (P = 0.021; Fig. 4).
Percent BF was defined as the percentage of the
original osseous defect filled with new bone as mea-
sured radiographically. Percent BF was significantly
increased at 6 months post-surgery in group 1 (57%
– 6%) and group 2 (34% – 4%) when compared
to group 3 (18% – 6%), yielding a P <0.001 and
P = 0.019, respectively (Fig. 5A). Subgroup analyses
of % BF were also performed to assess the effects of
smoking versus non-smoking and of defect morphol-
ogy. These analyses demonstrated that rhPDGF treat-
ment improved bone fill in smokers and in all defect
types (Figs. 5B and 5C, respectively).
To assess the predictability of the responses, the
cumulative percent bone fill was computed and the
cumulative distribution functions are displayed in Fig-
ure 6. The three treatment groups demonstrated sep-
aration, with group 1 consistently demonstrating the
best effectiveness. The cumulative distributions were
highest for group 1 followed by groups 2 and 3, re-
spectively, for any % BF threshold. That is, at any
given point on the curves, the cumulative percentage
Table 2.
No Significant Differences in Demographic Characteristics Between Groups
Group 1 (N = 60) Group 2 (N = 61) Group 3 (N = 59) P Value
Gender 0.074*
Female 31 (51.7%) 20 (32.8%) 21 (35.6%)
Male 29 (48.3%) 41 (67.2%) 38 (64.4%)
Ethnicity 0.387†
White 33 (55.0%) 37 (60.7%) 37 (62.7%)
Hispanic 6 (10.0%) 4 (6.6%) 8 (13.6%)
Asian 10 (16.7%) 13 (21.3%) 9 (15.3%)
African American 11 (18.3%) 5 (8.2%) 5 (8.5%)
Native American 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other 0 (0.0%) 2 (3.3%) 0 (0.0%)
Age (years) 0.222‡
Mean – SE 49.4 – 1.3 50.4 – 1.7 52.8 – 1.2
Minimum/maximum 27/67 23/73 29/71
Medical condition/medications
Diabetes (type I or II)
Yes 2 (3.3%) 7 (11.5%) 6 (10.2%) 0.163†
No 58 (96.7%) 54 (88.5%) 53 (89.8%)
Chronic non-steroidal anti-
inflammatory drug use
Yes 10 (16.7%) 7 (11.5%) 15 (25.4%) 0.268†
No 50 (83.3%) 54 (88.5%) 44 (74.6%)
Smoking history
Current smoker 12 (20.0%) 19 (31.1%) 12 (20.3%) 0.262‡
Number of cigarettes smoked
daily (mean – SE)
11.6 – 1.6 9.5 – 1.5 8.2 – 2.0 0.429‡
Number of cigars smoked
weekly (mean – SE)
0.0 – 0.0 0.0 – 0.0 0.1 – 0.1 0.438‡
Number of pipes smoked
weekly (mean – SE)
0.0 – 0.0 0.0 – 0.0 0.6 – 0.6 0.281‡
* Chi-square test.
† Fisher’s exact test.
‡ One-way ANOVA.
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of patients with the greatest bone fill was highest in
group1 compared to either group2or 3. For example,
50% of patients in group 1 exhibited >49% bone fill
compared to 20%bone fill in group3. AWilcoxon rank
sum test was used to compare the cumulative distri-
butions for groups 1 (P <0.0001) and 2 (P = 0.0572)
versus group 3. This overall comparison demon-
strated a consistent advantage for group 1 over group
3, which was independent of the % BF threshold.
Safety
The safety assessment included clinical examina-
tions and radiographs of adverse events, both serious
or non-serious and related or unrelated, to the treat-
ment groups. The most frequently experienced ad-
verse event for all treatment groups was study site
pain, a normal sequela to the surgical procedure (typ-
ically resolved within 1 week of surgery), followed by
headache. The study found no significant differences
in adverse events across the treatment groups. The
assessment of radiographs revealed no findings out-
side of normal limits for any treatment group.
DISCUSSION
Earlier clinical studies provided human histologic ev-
idence (‘‘proof of principle’’) that the combination of
purified rhPDGF-BB and a scaffolding material (bone
allograft) could result in substantial periodontal re-
generation.6,7 The present study was designed to
evaluate the safety and effectiveness of rhPDGF-BB
Figure 2.
Representative rhPDGF treated case. A) Baseline; B) initial osseous
defect on the distal of tooth #22 following thorough debridement;
C) b-TCP + rhPDGF completely filling the defect; D) 3-5 days post-
surgery showing excellent healing; E) clinical and (F) radiographic
appearance of baseline defect; G) 6-month surgical reentry showing
clinical defect fill; and H) 6-month radiograph showing defect fill.
Figure 3.
rhPDGF significantly improved CAL gain between baseline and
6 months as assessed by clinical improvement in CAL as a function
of time.
Figure 4.
rhPDGF-BB plus b-TCP significantly improved LBG compared to
b-TCP plus buffer.
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and a synthetic matrix in the largest prospective, ran-
domized, blinded, controlled, and multicenter human
clinical trial published to date on a periodontal regen-
erative therapy. A parallel design was used with each
patient contributing one defect, thereby eliminating
the potential for crossover treatment effects by the
growth factor. Randomization, the large sample size,
and the defect entry criteria assured comparable de-
fects across each treatment group, as evidenced by
the data shown in Tables 1 and 2. The current study
was designed to include practitioners in private office
settings and academic research clinics and was
independently monitored and analyzed in an attempt
to rigorously assess the safety and effectiveness of
this therapy.
The results of this clinical study confirmed earlier
extensive studies demonstrating the safety of rhPDGF
in multiple animal and human studies.6,7,56,57
Additionally, this study further confirms the beneficial
effects of rhPDGF observed in earlier human histologic
periodontal studies.6,7 The rhPDGF-BB (0.3 mg/ml
dose) significantly improved bone fill (LBG and %
BF) assessed radiographically at 6 months and soft
tissue outcomes at 3 months (CAL gain and reduced
GR) assessed clinically, compared to the active con-
trol, b-TCP. At 6 months, the CAL gain in group 1 re-
mained greater than group 3; however, the difference
was not significant due to an increase in the group
3 score. Significant improvements in both soft tissue
Figure 5.
A) rhPDGF-BB plus b-TCP significantly improved % BF of all bone
defects compared to b-TCP plus buffer. B) rhPDGF stimulated
a significant improvement in bone fill in smokers and non-smokers
(P <0.001), although bone fill tended to be greater in non-smokers
compared to smokers (P = 0.15 in the 0.3 mg/ml rhPDGF group). C)
rhPDGF treatment also resulted in significantly improved bone fill in
1-, 2-, and 3-wall defects (P <0.001); there was no significant
difference in bone fill between 1- and 2-wall defects compared to
3-wall and circumferential defects (P = 0.40 in the 0.3 mg/ml group).
Figure 6.
Percent bone fill cumulative distribution. The cumulative distributions
were highest for group 1 as this group exceeded the response seen in
groups 2 and 3 for any % BF threshold. For example, the horizontal
line illustrates that half of the patients in group 1 achieved greater
than 49% bone fill, whereas half of the patients in group 3 achieved
only 20% bone fill. AWilcoxon rank sum test was used to compare
the cumulative distributions for groups 1 (P <0.0001) and 2
(P = 0.0572) versus group 3.
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and bone measurements are important clinical
findings and are likely the result of PDGF’s stimula-
tory effects on periodontal ligament and bone
cells.24,43-55
The finding that the 0.3 mg/ml dose of rhPDGF-BB
was more effective than the 1.0 mg/ml dose is con-
sistent with preclinical studies in a canine model (un-
published observations) and reflects similar results
observed for other growth factors andcytokines, dem-
onstrating the potential for an inverse dose effect with
many biological mediators. This finding underscores
a fundamental observation that cytokines, such as
PDGF, may have differing effects based on local
concentration.52-54 Perhaps the most well known
example of this phenomenon is insulin, which also ex-
hibits a classic bell-shaped dose response curve in
which a low dose is ineffective, the proper dose pro-
vides the desired biological response, and a dose that
is too high is life-threatening. Although apparently not
as effective, even the high dose of rhPDGF-BB in this
trial did not result in any adverse effects.
The significant increase in the rate of CAL gain and
bone fill at 6 months is, to our knowledge, a unique
finding. Interestingly, a significant difference in bone
fill between study groups does not routinely correlate
with a significant difference in CAL, and vice versa,
particularly when the control employed is itself a bone
void fillermaterial. It has been shown that although the
latter materials frequently do not lead to periodontal
regeneration, they do result in the filling of the osseous
defect, which leads to substantial CAL gain. It is thus
more difficult to show significant improvements in
CALbetween test and control groupswhen the control
group receives a bone graft and/or bone graft substi-
tute rather than just open flap debridement alone. For
example, no significant difference inCALgainwasob-
served when a bovine bone mineral with synthetic
peptide was compared to the bovine bone mineral
alone, although the authors did observe a significant
improvement in bone fill.58
Given the potential for incongruent results between
soft tissue and bone measurements, both types of
measurements appear necessary to fully evaluate
a periodontal therapy. However, osseous reentry sur-
gery is impractical in all patients in a largemulticenter
clinical trial such as this, especiallywhenprivate prac-
tice settings are included. Therefore, this study used
radiographic analyses for LBGand%BF to provide in-
formation related to periodontal bone changes that
occurred following treatment. The digitized radio-
graphic format used in this trial, along with the use
of standardized methods and computer algorithms,
reduces the effect of potential errors encounteredwith
visual interpretation by examiners of a restricted two-
dimensional representation of the three-dimensional
anatomy. Additionally, vertical bone growth adjacent
to the root surface was chosen as a key outcome be-
cause changes in linear bone levels are easily under-
stood and present a clinically meaningful change in
the support of the tooth.Wewere fortunate in the pres-
ent study that b-TCP is absorbed over a period of sev-
eral months and thus did not obscure the bone fill.
Further, because both the controls and test groups in-
cluded the b-TCP, any increase in radioopacity that
might be caused by residualb-TCPwould presumably
be similar in all groups.
It is also noteworthy that radiographic assessment
of alveolar bone fill often underestimates actual bone
fill measured clinically (i.e., surgical reentry). Thus,
the current study results demonstrating a gain in ra-
diographic linear bone growth and percent bone fill
may actually underestimate these results as com-
pared to clinical reentry. The use of a centralized radi-
ology review center, which was independent of any
clinical center involved in patient care, also has the
virtue of being completely blinded and unbiased re-
garding patient outcome.
In summary, this 180-patient, randomized, con-
trolled, and blinded clinical trial demonstrated that
purified rhPDGF-BBmixed with a synthetic bone sub-
stitute was safe and effective for the treatment of peri-
odontal osseous defects. The significant increase in
the rate of CAL gain, reduction in gingival recession
at 3 months, and improvement in bone fill demon-
strated in this study provide substantial evidence for
the clinical advantages of this therapy. Moreover,
the findings of this study substantiate the hypothesis
that the addition of rhPDGF-BB improves the effec-
tiveness of the bone substitute.
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